Dr. Roy Fleischmann from the University of Texas Southwestern Medical Center in Dallas, Texas, presents a study of multiple switches between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis. The study was published in The Lancet Rheumatology in August 2023.